University of Michigan

The Dow Chemical Company

Dendritech Inc.

Anna U Bielinska

James R Baker, Jr

Paul E Makidon

Douglas M Smith

Jessica J O'Konek

Jessica Ann Knowlton

Luz Blanco

Tarek Hamouda

Andrzej Myc

Stewart C Wang

John LiPuma

Jeffery V Groom, Ii

Nicholas Mank

Mark R Hemmila

James R Baker

Nicholas J Mank

Luz P Blanco

Donald A Tomalia

William Jack Kruper, Jr

Ian A Tomlinson

Michael J Fazio

Larry R Wilson

David M Hedstrand

Roberta C Cheng

Bartley Dean Maxon

Rui Yin

Herbert M Brothers, Ii

Shraddha S Nigavekar

Jolanta F Kukowska-Latallo

Zhengyi Cao

Jennifer A Johnson

Alison J Scott

Scott L Klakamp

Donald A Kaplan, Deceased

Lars T Piehler

Jessica J O'KONEK

Jr James R Baker

Douglas Smith

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response. Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

The present invention relates to methods and compositions for stimulating an immune response. Specifically, the present invention provides methods of inducing an immune response to bacteria of the genus(e.g.,) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprisingor an immunogenic portion thereof). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination) and research applications.

[object Object]

The present invention relates to methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response to human immunodeficiency virus (HIV) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., a nanoemulsion comprising HIV or antigenic portion thereof).

Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen

The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides immunogenic compositions and methods of using the same to induce immune responses (e.g., immunity (e.g., protective immunity)) against Hepatitis B virus (HBV)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same

The present invention relates to therapeutic nanoemulsion compositions and to methods of utilizing the same. In particular, nanoemulsion compositions are described herein that find use in the treatment and/or prevention of infection (e.g., respiratory infection (e.g., associated with cystic fibrosis)), in burn wound management, and in immunogenic compositions (e.g., comprising aantigen) that generate an effective immune response (e.g., against a bacterial species of the genus) in a subject administered the immunogenic composition. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

Nanoemulsion therapeutic compositions and methods of using the same

The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods of inducing an immune response against one or a plurality of pathogens (e.g., vaccinia virus, H5N1 influenza virus,, Hepatitis B, and/or HIV, etc.) in a subject (e.g., a human subject) and compositions useful in such methods (e.g., immunogenic composition comprising nanoemulsion and one or a plurality of pathogens (e.g., inactivated by the nanoemulsion) and/or pathogen products and/or pathogen components). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.

Multivalent nanoemulsion vaccines

Dendritic polymer conjugates which are composed of at least one dendrimer in association with at least one unit of a carried material, where the carrier material can be a biological response modifier, have been prepared. The conjugate can also have a target director present, and when it is present then the carried material may be a bioactive agent. Preferred dendritic polymers are dense star polymers, which have been complexed with biological response modifiers. These conjugates and complexes have particularly advantageous properties due to their unique characteristics.

Bioactive and/or targeted dendrimer conjugates

Growing community of inventors

Ann Arbor, MI, United States of America

Anna U Bielinska